Novartis Pharmaceuticals has agreed to a deal with GlaxoSmithKline to buy an experimental multiple sclerosis drug. The drug, ofatumumab, will be used by Novartis to treat cancer, remitting multiple sclerosis, and other autoimmune conditions and will be sold under the name Arzerra. Novartis has agreed to pay up to $1 billion to Glaxo under the […]
↧
